Aktie A2PGMX TURG POIN
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen TURG POIN

Aktien

A2PGMX

US90041T1088

TPTX

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from S&P Global BMI Index
Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from S&P Biotechnology Select Industry Index
Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from S&P TMI Index
Bristol-Myers Squibb Completes Acquisition of Turning Point Therapeutics
Turning Point Therapeutics : Termination of a Material Definitive Agreement - Form 8-K
TURNING POINT THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
Turning Point Therapeutics, Inc. Announces Executive Changes
Turning Point Therapeutics, Inc.(NasdaqGS:TPTX) dropped from NASDAQ Composite Index
Bristol Myers, Turning Point Say Regulatory Waiting Period for Acquisition Expires; Deal to Close Wednesday
Bristol-Myers Squibb Company completed the acquisition of Turning Point Therapeutics, Inc. from a group of shareholders..
Biotech stocks pin bounce back hopes on M&A boost
Turning Point Therapeutics : Positive feedback from pre-new drug application (NDA) meeting with U.S. Food and Drug Administration (FDA) focused on TRIDENT-1 registrational study of repotrectinib Initiated the Phase 1b/2 SHIELD-2 combination study of elzovantinib and aumolertinib in EGFR mutant MET-amplified advanced non-small cell lung cancer (NSCLC) Plan to provide detailed update for TRIDENT-1 registrational ROS1-positive NSCLC population and additional data for NTRK-positive solid tumor population, as we
Turning Point Therapeutics: Q2 Earnings Snapshot
TURNING POINT THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
Turning Point Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Turning Point Therapeutics Reports Second-Quarter 2022 Financial Results, Provides Operational Updates
Turning Point Therapeutics, Inc. Provides Operational and Clinical Update
Turning Point Therapeutics Provides Regulatory Update for Repotrectinib for the Treatment of ROS1+ Advanced NSCLC
HBM Healthcare Investment: 51,6 millions de francs de bénéfice trimestriel
Bristol Myers Squibb Extends Turning Point Tender Offer
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2PGMX Aktie
  4. Nachrichten TURG POIN
  5. Andere Sprachen